rather decreased bilirubin levels in general than the changes in the genetic variation of this gene that increase the risk for CAD.
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Introduction
Several studies have shown that bilirubin, a major product of heme catabolism, has a potent antioxidative capacity (Stocker et al., 1987; Neuzil et al., 1994) . Animal experiments in congenitally hyperbilirubinemic Gunn rats with a defective uridinediphosphate-glucuronosyltransferase compared to wildtype rats demonstrated virtually no neointimal proliferation after intimal injury caused by balloon angioplasty.
When wildtype rats were pretreated with the bilirubin precursor biliverdin before injury, neointimal formation was also significantly reduced. Cultured vascular smooth muscle cells from rats showed a significantly reduced proliferation when treated with bilirubin (Öllinger et al., 2005) . These properties and bilirubin's ability to scavenge peroxyl radicals indicates a protective role of bilirubin against vascular aging and associated atherosclerotic diseases (Schwertner et al., 2008) . This is in line with epidemiological studies reporting low serum bilirubin levels to be associated with an increased risk for coronary artery disease (CAD) or other atherosclerosis outcomes show an inverse association with the transcriptional activity (Bosma et al., 1995) . So far five different alleles with (TA) 5-9 -repeats have been described with (TA) 6 and (TA) 7 repeats as the main alleles with a frequency of up to 60% and 40%, respectively, in 4
Caucasian populations (Beutler et al., 1998 A recent study in 11 Japanese and 12 Caucasian patients with Gilbert's syndrome reported homozygosity for both, the UGT1A1 -53(TA) 7 
Patients and Methods

Patients and Controls
This case-control study is based on 1096 individuals of European ancestry from the same geographical region of Utah who are known to have little racial admixture.
The 477 patients (365 men and 112 women) with premature, familial CAD had survived a myocardial infarction, percutaneous transluminal angioplasty, or coronary artery bypass grafting before age 55 for men or age 65 for women. To minimize artifactual effects of the acute coronary syndrome on biochemical measurements, patients were seen at least 6 months after their acute event. Each of the CAD cases was from a family in which at least one additional first-degree relative had early CAD by this definition. The control group is based on 833 individuals representing a general population sample from the same geographical region as described recently (Schoenborn et al., 2006) . From this control group we selected 397 men and 222 5 women who represented a similar age distribution as the respective gender-specific patient groups and which can be considered as an approximate 1:1 matching for men and 1:2 matching for women (patients:controls). Ethical approval by local committee and written informed consent was obtained from each participant.
Bilirubin measurement
All biochemical measurements were made in overnight fasting venous samples.
Total serum bilirubin was measured by a thin film adaptation of a diazonium salt, colorimetric method using the Vitros analyzer (Ortho-Clinical Diagnostics, Inc.
Rochester NY 14650).
Genotyping
The UGT1A1 -53(TA-repeat) promoter polymorphism was analyzed by the ABI 3130xl sequencing system exactly as described recently (Lin et al., 2006) . The -3279T>G polymorphism (rs4124874) was determined by use of a 5'-Nuclease Assay and the ABI Prism® 7900HT system. Additionally 10 % of the samples were genotyped in duplicate for quality control. Genotyping was performed within the Genotyping Unit of the Gene Discovery Core Facility at the Innsbruck Medical University, Austria.
Statistical analysis
To compare characteristics of patients and controls, we applied unpaired t-tests 
Results
Baseline characteristics
The demographic and laboratory parameters of the 477 CAD patients and the 619 controls are presented in Table 1 . All analyses were stratified by gender. In both genders cases showed higher concentrations of total cholesterol, LDL-cholesterol, triglycerides, glucose and serum creatinine and lower levels for HDL-cholesterol and albumin concentrations as expected. A higher frequency of current smokers and exsmokers was found among the cases. Serum bilirubin levels were about 20% lower in CAD patients compared to controls of both genders. Independent of case status, females exhibited lower bilirubin concentrations compared to males (p<0.001).
Genotype characteristics
Lewontin's D' of the -53(TA) and T-3279G locus was almost unity (D'=0.9969) with a correlation coefficient of r=0.77. There were no statistical significant differences in the genotype distribution when comparing men and women or when comparing cases and controls. The minor allele frequencies for the -53(TA-repeat) and the T-3279G polymorphism ranged between 30.7% and 31.9% and between 42.5 and 49.1%, respectively, in the four subgroups, male and female controls or patients ( Table 2 ).
Bilirubin concentrations depend on UGT1A1 polymorphisms (analysis stratified by case-control status)
We observed strong associations between both polymorphisms and bilirubin levels in the case control-stratified analysis (Table 2 ). Homozygote carriers of the minor allele of the -53(TA-repeat) polymorphism showed the highest bilirubin concentrations. Heterozygote individuals showed bilirubin levels closer to the levels of homozygote wildtypes. These associations were very strong in the recessive model in male controls (p=5.9x10 -26 ), male CAD patients (p=3.4x10 -16 ) and female 7 CAD patients (p=0.00001), but were of borderline significance in female controls (p=0.09). Similar observations but with less strong effect sizes were observed for the T-3279G polymorphism ( Table 2 ).
The total variation of bilirubin levels explained by the two polymorphisms combined was 15.4% in cases, and 13.6% in controls ( Table 3 ). The analysis of the variation of bilirubin levels explained by the two single polymorphisms separately revealed that the T-3279G polymorphism explained less of the bilirubin variation than the -53(TA-repeat) polymorphism.
Bilirubin concentrations depend on CAD case-control status (analysis stratified by genotype groups)
When analyzing the genotype-specific differences in bilirubin levels between patients and controls, highly significantly lower bilirubin levels were observed among CAD patients compared to controls when focusing on subjects homozygous for the major allele (6/6 or T/T) or heterozygous (6/7 or T/G) (see most right column of Table   2 with p values ranging from 0.0004 to 1.0x10
). For subjects homozygous of the minor allele (7/7 or G/G), we observed a trend towards lower bilirubin levels in men (p=0.06 and 0.07 for the -53(TA-repeat) and the T-3279G polymorphism, respectively), but no difference in women (p=0.15 and 0.32, respectively).
Haplotype analysis
In concordance with the single polymorphism analysis, individuals carrying two copies of the major allele of both polymorphisms had the lowest bilirubin levels and haplotypes based on the minor allele at both SNPs were associated with the highest bilirubin levels (data not shown).
Association of bilirubin concentrations with CAD outcome, but no association of the polymorphisms with CAD outcome
After adjustment for age (model 1) and other risk factors (models 2 and 3), we observed a significant decrease in CAD risk per 0.1 mg/dl increase in serum bilirubin concentrations of about 6-10% in men and for about 25% in women (Table 4) . No significant change in CAD risk depending directly on the genotype groups of the two polymorphisms was observed. that low serum bilirubin levels were associated with increased risk for coronary events.
Genetic variation within the UGT1A1 gene and CAD
Two polymorphisms in the promoter region of the UGT1A1 gene, the -53(TArepeat) and the T-3279G polymorphism, were shown to be strongly associated with There are several explanations which might have contributed that we did not find an association of the UGT1A1 polymorphisms with CAD and some of them were discussed in detail recently by Schwertner and Vítek (Schwertner et al., 2008) . The first one is the case-control design of our study. Due to the fact that all included cases in our study had survived a CAD event for at least six months, we might speculate on a survival bias considering that about half of the incident cases do not survive the first half year of a CAD event and that the further survival after the first event is influenced by genetic factors (Marin et al., 2005) . Given this hypothesis, the fact that we still detected the association of bilirubin levels with CAD might be explained by the strengths of this association and the situation that the UGT1A1 polymorphisms explain only about 10-15% of the bilirubin variance (Table 3 ). An for not finding an UGT1A1 association with CAD is a lack of power. If increased bilirubin levels cause a decreased risk of CAD of 10-25% per unit bilirubin, we have sufficient power to find this association. However, since the polymorphism shows various expressivity within each genotype group, the polymorphism explains only 10-15% of the variation in bilirubin levels. Therefore, our ability to detect this polymorphism-CAD association drops substantially if we consider also the fact that the frequency of the -53(TA) 7/7 genotype in CAD patients was expected to be half of the controls in case of a power of 80%.
Under the hypothesis that the UGT1A1 polymorphisms' changes decreased CAD directly, we would expect an equally strong or even stronger association of the polymorphism with CAD than the association of bilirubin levels with CAD. As this was not the case, we can conclude that it is low bilirubin levels in general that seem to increase CAD risk than just the UGT1A1 polymorphisms. Interestingly, the recent genome-wide association study by the Wellcome Trust Case Control Consortium did not find a significant association of the UGT1A1 gene region with CAD (The Wellcome Trust Case Control Consortium 2007).
Gender differences
Hunt and colleagues (Hunt et al., 2001 ) reported a borderline significant difference in serum bilirubin levels between CHD cases and controls in males (p=0.08) but no differences in females. Similar results were found by Endler et al. (Endler et al., 2003) . Our study found an association of low bilirubin levels with CAD in both genders, which was even stronger in females: logistic regression analysis revealed a decreasing risk for CAD of about 10% and 25% for men and women, respectively, with each increase of bilirubin of 0.1 mg/dl. Similarly, Erdogan et al. (Erdogan et al., 2006) found an association in both, men and women. Reasons for these contrasting results might be the small number of women with the investigated outcomes and therefore low power or major age differences between women cases and controls. Interestingly, the association of the two investigated polymorphisms with bilirubin levels was much smaller in female controls than in male controls but still very strong in both genders of cases (Table 2 ).
Limitations of the Study
We did not adjust our findings for liver enzymes since these parameters were not available in the entire group. However, when we performed a sensitivity analysis in those patients and controls with alkaline phosphatase (ALP), aspartate transaminase (AST), or gammaglutamyltransferase (GGT) available, we observed similar results as described above (data not shown).
A stratified analysis of subjects with hyperbilirubinemia above 1 mg/dL was not suitable since the frequency of this state was only 4.3% and 12.5% in females and males, respectively.
We did not investigate further polymorphisms in the region of UGT1A1. Hong et al. reported besides the TA repeat polymorphism 14 other SNPs and demonstrated that conditional on the TA repeat polymorphism no other variant was shown to be significantly associated with bilirubin in both genotype and haplotype analyses (Hong et al., 2007) . According to this thorough study, we have already tagged the common haplotypes with the two polymorphisms investigated in our study. If there is indeed an additional variant which contributes to bilirubin levels independent from the TA repeat polymorphism, it can be expected that the effect is quite small which would require a large sample size.
Conclusion
In summary, the present case-control study showed a strong and consistent association of low serum bilirubin levels with CAD for both genders. Despite a clear association of the two analyzed UGT1A1 promoter polymorphisms with bilirubin concentrations, we could not detect a significant association of these polymorphisms with CAD indicating that it is rather decreased bilirubin levels in general than the changes in the gene product caused by the particular polymorphisms that increase the risk of CAD. Minor allele frequency=49.1% Minor allele frequency=47.5% a The mean bilirubin levels are the retransformed mean bilirubin levels computed on the ln(bilirubin+1) scale. b p values from linear regression adjusted for age to compare bilirubin levels between the genotype groups within controls or CAD cases. The additive genetic model calculates the p values for the changes of mean bilirubin levels per copy of the minor allele. The recessive genetic model calculates the p values for the changes of mean bilirubin levels of subjects with two copies of the minor allele versus subjects with only one or no copy of the minor allele. c p values from linear regression adjusted for age to compare bilirubin levels between controls and CAD cases with the same genotype group. 20 Table 4 : Logistic regression analysis adjusted for age and stratified for gender investigating the association of bilirubin concentrations and the -53(TA-repeat) and the T-3279G polymorphisms (genotypes) on the change of odds for coronary artery disease (CAD).
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Values given are the odds ratio (OR), 95% confidence intervals (CI), and the respective pvalue testing for deviance of the OR from unity.
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